Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?

International Clinical Psychopharmacology

Volumn 24, Issue 3, 2009, Pages 111-118

  Montgomery, Stuart A ^a,c   Möller, Hans Jürgen ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF MUNICH   (Germany)

^c NONE   (United Kingdom)

Author keywords

Clinical relevance; Escitalopram; Remission; Responders; Treatment effect

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CLINICAL ASSESSMENT; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; HUMAN; LOW DRUG DOSE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; REMISSION; REVIEW; SHORT COURSE THERAPY; TREATMENT RESPONSE; COMPARATIVE STUDY; MAJOR DEPRESSION; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHIATRIC STATUS RATING SCALES;

EID: 67649206008     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32832a8eb2     Document Type: Review

References (23)

1. Auquier P, Robital S, Llorca PM, Rive B (2003). Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatr Clin Pract 7:259-268.
2. Boulenger JP, Huusom AKT, Florea I, Baekdal T, Sarchiapone M (2006). A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 22:1331-1341.
3. Committee for Proprietary Medicinal Products (2002). Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Depression. The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use, CPMP/EWP/518-97-Rev.1.
4. Gorman JM, Korotzer A, Su G (2002). Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 7 (Suppl 1):40-44.
5. Hamilton M (1967). Development of rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
6. Kasper S, Spadone C, Verpillat P, Angst J (2006). Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 21:105-110.
7. Kennedy SH, Andersen HF, Lam RW (2006). Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 31:122-131.
8. Khan A, Leventhal RM, Khan SR, Brown WA (2002). Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 22:40-45.
9. Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C (2007). Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Invest 27:481-492.
10. Kirsch I, Moore TJ, Scoboria A, Nicholls SS (2002). The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevention & Treatment 5:23.
11. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:e45.
12. Lam RW, Andersen HF, Wade AG (2008). Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials. Int Clin Psychopharmacol 23:181-187.
13. Lepola U, Wade AG, Andersen HF (2004). Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 19:149-155.
14. Llorca P-M, Azorin J-M, Despiegel N, Verpillat P (2005). Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 59:268-275.
15. Melander H, Salmonson T, Abadie E, van Zwieten-Boot B (2008). A regulatory apologia - a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur J Neuropsychopharmacol 18: 623-627.
16. Montgomery SA, Andersen HF (2006). Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 21:297-309.
17. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
18. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, et al. (2007). Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 22:323-329.
19. Moore N, Verdoux H, Fantino B (2005). Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 20:131-137.
20. Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM (2007). Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 23:401-416.
21. Thase ME, Entsuah AR, Rudolph R (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:241.
22. Wade AG, Gembert K, Florea I (2007). A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 23:1605-1614.
23. Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV (2007). Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 29:2319-2332.